Share:
A second daily dose of dolutegravir for people taking standard TB treatment seems to be unnecessary, a South African randomised study has reported in the journal Lancet HIV.
Read the full story at Aidsmap.
For more TB news, check out the latest edition of the TB Online Weekly Newsletter (#20, 18 June 2023) with the latest TB advocacy and research updates.
Source : Aidsmap
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.